Autobio Diagnostics (603658) Q4 2024 earnings summary

Executive summary

• Revenue reached ¥4.47 billion, up 0.62% year-over-year; net profit attributable to shareholders was ¥1.19 billion, down 1.89% year-over-year.

• R&D investment hit ¥731.93 million, 16.37% of revenue, with 1,982 R&D staff (34.33% of total employees).

• Cash dividend of ¥1.26 per share (total ¥719.99 million), plus share repurchase, returned 96.81% of net profit to shareholders.

• Company maintained strong innovation, launching new products and expanding in NGS, mass spectrometry, and AI-driven diagnostics.

Financial highlights

• Operating income: ¥4.47 billion (+0.62% YoY); net profit: ¥1.19 billion (-1.89% YoY).

• Gross margin for IVD business: 66.03%; overall gross margin stable.

• Basic EPS: ¥2.07; ROE: 13.92%; net assets: ¥8.62 billion.

• Operating cash flow: ¥1.31 billion (-10.92% YoY); investment cash flow: -¥1.19 billion.

• R&D expenses up 11.55% YoY; sales and admin expenses increased moderately.

Outlook and guidance

• Focus on expanding R&D in sequencing, mass spectrometry, and POCT.

• Plans to optimize resource allocation, expand sales, and improve operational efficiency amid industry price pressures and consolidation.

• Company expects to leverage broad product lines and scale to maintain competitiveness.